Optimizing Vancomycin Dosing and Monitoring in Neonates and Infants Using Population Pharmacokinetic Modeling
Praneeth Jarugula, Ayse Akcan‐Arikan, Flor M. Muñoz, Brady S. Moffett, Vijay Ivaturi, Danielle R. Rios
Abstract
We determined optimal vancomycin starting dose regimens in infants ≤180 days of age to achieve the highest probability of target attainment with an area under the concentration-time curve for 24 h (AUC 24 ) of ≥400 using population pharmacokinetic (PK) modeling. Secondarily, determination of the relationship between serum creatinine (SCR) and vancomycin clearance in neonates was done.
Topics & Concepts
DosingVancomycinPharmacokineticsMedicinePopulationTrough ConcentrationRenal functionCreatinineQuartileClearanceInternal medicineUrologyConfidence intervalBiologyStaphylococcus aureusBacteriaGeneticsEnvironmental healthAntimicrobial Resistance in StaphylococcusAntibiotics Pharmacokinetics and EfficacyPneumonia and Respiratory Infections